KRAS and lung adenocarcinoma: Taken together, our data suggest that the loss of the WT allele in KRAS mutant lung adenocarcinomas is often associated with G12C and G12V mutations, and the loss of the WT copy of the KRAS gene modulates response to treatment with compounds targeting KRAS downstream substrates.